Actionable news
All posts from Actionable news
Actionable news in CYTK: Cytokinetics, Incorporated,

Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016


Cytokinetics, CYTK, +2.60% announced today that a poster presentation on additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2b trial evaluating omecamtiv mecarbil in patients with chronic heart failure, will be presented at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology, to be held May 21 - May 24, 2016 at the Fortezza da Basso in Florence, Italy.

Poster Title: Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): Improved Contractility and Evolution of Ventricular Remodelling Through Time
Speaker: John Teerlink, M.D., professor of Clinical Medicine at the University of California San Francisco and director of Heart Failure at the San Francisco Veterans Affairs Medical Center
Session Title: Clinical Forum
Date: Saturday, May 21, 2016
Time: 8:30 AM - 5:30 PM
Poster Number: P2206

About Omecamtiv Mecarbil

Omecamtiv mecarbil is a novel cardiac myosin activator. Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction. Cardiac myosin activators are thought to accelerate the rate-limiting step of the myosin enzymatic cycle and shift the enzymatic cycle in favor of the force-producing state. Preclinical research has shown that cardiac myosin activators increase contractility in the absence of changes in intracellular calcium in cardiac myocytes. Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics. Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization rights. Les Laboratoires Servier obtained an exclusive option to commercialize omecamtiv mecarbil in Europe.